Skin Cancer Clinical Trial
Official title:
Using a Narrative-Based Approach to Reducing Indoor Tanning
Verified date | December 2021 |
Source | University of Connecticut |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this research is to develop a social media delivered intervention to reduce unprotected sun exposure in young adults with a history of tanning.
Status | Completed |
Enrollment | 66 |
Est. completion date | October 28, 2020 |
Est. primary completion date | October 28, 2020 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 30 Years |
Eligibility | Inclusion Criteria: - Ages 18-30 - Tanned indoors or outdoors at least once in the past year - Intends to tan indoors or outdoors this summer - Daily user of any social media platform Exclusion Criteria: - No smartphone - Does not use a social media platform daily - Lives in a state with an average temperature <75 degrees in May - Inability to provide consent due to mental illness or a cognitive impairment - Non-English speaking - Prisoner |
Country | Name | City | State |
---|---|---|---|
United States | University of Connecticut | Storrs | Connecticut |
Lead Sponsor | Collaborator |
---|---|
University of Connecticut | National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Recruitment | The number of completed respondents to recruitment ads, number of respondents eligible at initial screening, and number of respondents who completed baseline. | Baseline | |
Primary | Retention | The % of participants in each condition who complete the follow-up assessment. | 4-week follow-up | |
Primary | Acceptability | Number of participants who selected agree or strongly agree on 5-point Likert scale rating of how likely participants would be to recommend the intervention to a friend, and how likely they would be to participate again. | 4-week follow-up | |
Primary | Participation | The number of posts created by participants | 4-week follow-up | |
Primary | Post Engagement | The median number of likes, shares and retweets, and unique commenters each participant post received. | 4 weeks | |
Primary | Desirability of Tanning | Scale measuring participants' belief that a tan is attractive. Scale ranges from 0-12 with higher scores indicating higher levels of belief that a tan is attractive. | Baseline | |
Primary | Desirability of Tanning | Scale measuring participants' belief that a tan is attractive. Scale ranges from 0-12 with higher scores indicating higher levels of belief that a tan is attractive. | 4-week follow-up | |
Primary | Desirability of Tanning Alternatives | Average score on items relating to tanning alternative desirability. Scale ranges from 1 to 5, with higher scores indicating more positive attitudes towards tanning alternatives. | Baseline | |
Primary | Desirability of Tanning Alternatives | Average score on items relating to tanning alternative desirability. Scale ranges from 1 to 5, with higher scores indicating more positive attitudes towards tanning alternatives. | 4-week follow-up | |
Primary | Persuasive Impact of Participant Messages | The mean of participants ratings for how persuasive they found each post (other than those they created) on a scale of 0-100, with higher scores indicating more persuasive. | 4-week follow-up | |
Primary | Contamination | The number of participants who report they saw the opposite conditions Facebook or Twitter feeds. | 4-week follow-up | |
Secondary | Outdoor Tanning Intentions | Three items assessed intentions to tan even once, intentions to tan regularly in the next year, and intentions to quit on a 7-point scale (0=definitely will not, 6=definitely will). | Baseline | |
Secondary | Outdoor Tanning Intentions | Three items assessed intentions to tan even once, intentions to tan regularly in the next year, and intentions to quit on a 7-point scale (0=definitely will not, 6=definitely will). | 4-week follow-up | |
Secondary | Sun Exposure | How many hours the participant spent outside per week between the hours of 10am and 4pm. | Baseline | |
Secondary | Sun Exposure | How many hours the participant spent outside per week between 10am and 4pm | 4-week follow-up | |
Secondary | Outdoor Tanning | How many times in the last 4 weeks the participant went outside for the purpose of tanning in the sun. | Baseline | |
Secondary | Outdoor Tanning | How many times in the last 4 weeks the participant went outside for the purpose of tanning in the sun. | 4-week follow-up | |
Secondary | Sun Protection | Number of participants who reported using sun protection (sunscreen, protective clothing) often or always in the past month | Baseline | |
Secondary | Sun Protection | Number of participants who reported using sun protection (sunscreen, protective clothing) often or always in the past month | 4-week follow-up | |
Secondary | Indoor Tanning Behavior | Number of indoor tanning visits in the previous month | Baseline | |
Secondary | Indoor Tanning Behavior | Number of indoor tanning visits in the previous month | 4 weeks | |
Secondary | Sunburn | Number of participants with 1 or more sunburns in the past month | baseline | |
Secondary | Sunburn | Number of participants with 1 or more sunburns in the past month | 4 weeks | |
Secondary | Outdoor Tanning Duration | Median reported average number of minutes tanned per episode in the past 4 weeks, among participants who tanned in the past 4 weeks. | 4 weeks | |
Secondary | Outdoor Tanning Duration | Median reported average number of minutes tanned per episode in the past 4 weeks, among participants who tanned in the past 4 weeks. | Baseline |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT02721459 -
XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma
|
Phase 1 | |
Completed |
NCT03740815 -
Feasibility of Serratus Plane Block Associated With Sedation in Axillary Dissection
|
N/A | |
Recruiting |
NCT05779423 -
Cryoablation+Ipilimumab+Nivolumab in Melanoma
|
Phase 2 | |
Terminated |
NCT01468818 -
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma
|
Phase 2 | |
Completed |
NCT01820234 -
Evaluation of Store-and-Forward Teledermatology Versus a Face-to-Face Assessment During a Skin Cancer Screening Event
|
N/A | |
Completed |
NCT00535769 -
Evaluation of Adherence to Topical Agents: Applying Communication Technology to Improve Sunscreen Use
|
Phase 0 | |
Completed |
NCT00526032 -
Melanoma Detection by Oblique-Incidence Optical Spectroscopy
|
N/A | |
Completed |
NCT00588341 -
Phase II Trial of Neoadjuvant Temozolomide in Melanoma Patients With Palpable Stage III or IV Disease Undergoing Complete Surgical Resection
|
Phase 2 | |
Active, not recruiting |
NCT01447199 -
The Molecular Predisposition to Hereditary Nonpolyposis Colon Cancer (HNPCC)
|
||
Enrolling by invitation |
NCT04758988 -
AI Augmented Training for Skin Specialists
|
N/A | |
Not yet recruiting |
NCT04534868 -
Patient Acceptance And Satisfaction of Teledermoscopy In General Practice In a Belgian Rural Area
|
N/A | |
Recruiting |
NCT04138342 -
Topical Fluorescent Nanoparticles Conjugated Somatostatin Analog for Suppression and Bioimaging Breast Cancer
|
Phase 1 | |
Completed |
NCT03673917 -
Cosmetology Students and Skin Cancer
|
N/A | |
Recruiting |
NCT04341064 -
Sun-safe Habits Intervention and Education
|
Phase 3 | |
Completed |
NCT04206995 -
Cancer Sensing: Evaluation of Odour Sampling Techniques
|
||
Recruiting |
NCT05574101 -
A Study of Radiation Therapy and Cemiplimab for People With Skin Cancer
|
Phase 2 | |
Not yet recruiting |
NCT05860881 -
Topical Sirolimus in Chemoprevention of Facial Squamous Cell Carcinomas in Solid Organ Transplant Recipients (SiroSkin)
|
Phase 3 | |
Completed |
NCT05146622 -
Virtual Sun Safe Workplaces Ph I
|
||
Recruiting |
NCT05068310 -
Applicability of a Cellular Resolution Full-field OCT Image System for Pigmented and Non-pigmented Skin Tumors
|
||
Recruiting |
NCT03889899 -
Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia.
|
N/A |